Targovax has completed patient enrollment in the phase I trial with ONCOS-102 in combination with Keytruda in patients with advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma.
In this trial, ONCOS-102 immune activation is being tested in patients with advanced, unresectable melanoma